Biotech

Insofar as medical innovation is the future of health care, however, we are now seeing that health care plays a central role in the future of our economy.

The guidance released today by the Internal Revenue Service (IRS) describes the process by which firms can apply to have their research projects certified as eligible for the credit.

In contrast to rumors that have been floating around, the program is not set up on a “first come, first served” basis.

Companies working on projects that have "significant potential" to produce new drugs, find a cure for cancer, or address unmet medical needs can apply for up to a $5-million share of the funds.

The average pay for participants is $25 per hour; studies can pay up to $500 total.

Few people in Seattle know much about Hood’s nonprofit research center, and it puzzles more than a few biologists, but it has definitely been on a roll the past couple years.

Hood has received 17 honorary degrees from institutions such as Johns Hopkins, Yale, UCLA and Whitman College. He has published more than 650 peer-reviewed papers, received 15 patents, co-authored textbooks in biochemistry, immunology, molecular biology and genetics, and is just finishing a textbook on systems biology. In addition, he coauthored a popular book on the human genome project titled, The Code of Codes.

Smart, early innovators have sights set on the Pacific Northwest. Soon, everyone will follow.

“We are very pleased with the investor reception of our business model. Over the last nine years, Bacterin’s team of highly experienced professionals have worked diligently developing and perfecting its technology and creating a facility that would position the company to effectively market and deliver innovative products to the orthopedics industry." Guy Cook, Bacterin’s founder and CEO

Recommendations that would undermine the the technology transfer objectives of the Bayh-Dole Act and the biotech industry generally in the United States.